# Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

> **NCT02890719** · PHASE3 · WITHDRAWN · sponsor: **Fundacion Clinic per a la Recerca Biomédica**

## Conditions studied

- Liver Transplantation
- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir 100 mg/day
- **DRUG:** Elbasvir 50 mg/d
- **DRUG:** Grazoprevir 100 mg/day
- **DRUG:** Elbasvir 50 mg/day
- **DRUG:** Ribavirin 1200 mg/day

## Key facts

- **NCT ID:** NCT02890719
- **Lead sponsor:** Fundacion Clinic per a la Recerca Biomédica
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-08-03
- **Primary completion:** 2017-06-01
- **Final completion:** 2017-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Impossibility of supplying the medication in research of the study by the pharmaceutical company that gave it to the trial
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02890719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02890719, "Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02890719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*